文献速递肿瘤 PET/CT

18F-FDG PET/CT 对初治鼻咽癌的治疗获益

Benefit of [18F]-FDG PET/CT for treatment-naïve nasopharyngeal carcinoma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-09-01

该研究基于 460 枚活检淋巴结比较 PET/CT 与 MRI 诊断效能,并通过倾向匹配比较 T3N1M0 患者生存;PET/CT 诊断淋巴结敏感性、准确性和 AUC 更高,分期更准确并带来生存获益,基于 SUVmax-N 等指标的影像评分模型可识别高危患者并指导诱导化疗。

要点

  • PET/CT 诊断淋巴结的敏感性、准确性和 AUC 均优于 MRI。
  • PET/CT 分期较 MRI 单独分期带来更高生存率。
  • 基于 SUVmax-N、淋巴结坏死和结外侵犯的评分模型可识别高危患者。

核心结论

  • PET/CT 因更准确诊断淋巴结而在鼻咽癌分期中具优势,并贡献生存获益。
  • PET/CT 联合 MRI 提供的预后因素可识别高危患者并指导个体化治疗。

研究设计与样本

  • 基于 460 枚活检淋巴结比较 PET/CT 与 MRI 的诊断效能。
  • 采用倾向匹配方法比较 T3N1M0 患者中接受与未接受 PET/CT 者的生存差异。
  • 在 T3N1M0 患者子集中建立并检验影像评分模型。

主要发现

  • PET/CT 诊断淋巴结的敏感性 96.7% 对 88.5%(p < 0.001),准确性 88.0% 对 81.1%(p < 0.001),AUC 0.863 对 0.796(p < 0.05)。
  • MRI 分期的 T3N0-3M0 患者生存率无差异,而按 PET/CT 分期均为 T3N1M0。
  • PET/CT 联合 MRI 分期者生存率高于 MRI 单独分期者(p < 0.05),与 EBV DNA 载量无关。
  • SUVmax-N、淋巴结坏死和结外侵犯对生存有高度预测价值。
  • 基于上述因素的影像评分模型风险分层 C-index 为 0.72。

临床怎么用

  • 初治鼻咽癌分期可考虑 PET/CT 联合 MRI 以提高淋巴结诊断准确性。
  • 可利用 SUVmax-N、淋巴结坏死和结外侵犯等指标识别高危患者。
  • 对影像评分模型筛选的高危患者可考虑诱导化疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To test the advantages of positron emission tomography and computed tomography (PET/CT) for diagnosing lymph nodes and staging nasopharyngeal carcinoma and to investigate its benefits for survival and treatment decisions. METHODS: The performance of PET/CT and magnetic resonance imaging (MRI) in diagnosis was compared based on 460 biopsied lymph nodes. Using the propensity matching method, survival differences of T3N1M0 patients with (n = 1093) and without (n = 1377) PET/CT were compared in diverse manners. A radiologic score model was developed and tested in a subset of T3N1M0 patients. RESULTS: PET/CT performed better than MRI with higher sensitivity, accuracy, and area under the receiver operating characteristic curve (96.7% vs. 88.5%, p < 0.001; 88.0% vs. 81.1%, p < 0.001; 0.863 vs. 0.796, p < 0.05) in diagnosing lymph nodes. Accordingly, MRI-staged T3N0-3M0 patients showed nondifferent survival rates, as they were the same T3N1M0 if staged by PET/CT. In addition, patients staged by PET/CT and MRI showed higher survival rates than those staged by MRI alone (p < 0.05), regardless of the Epstein-Barr virus DNA load. Interestingly, SUVmax-N, nodal necrosis, and extranodal extension were highly predictive of survival. The radiologic score model based on these factors performed well in risk stratification with a C-index of 0.72. Finally, induction chemotherapy showed an added benefit (p = 0.006) for the high-risk patients selected by the model but not for those without risk stratification (p = 0.78). CONCLUSION: PET/CT showed advantages in staging nasopharyngeal carcinoma due to a more accurate diagnosis of lymph nodes and this contributed to a survival benefit. PET/CT combined with MRI provided prognostic factors that could identify high-risk patients and guide individualized treatment.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Yang SS, Wu YS, Chen WC, et al. Benefit of [18F]-FDG PET/CT for treatment-naïve nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2021. PMID: 34468782. doi:10.1007/s00259-021-05540-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。